Article Text

Download PDFPDF
Prion disease: clinical pathway development for the terminally ill

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • X @drchlo, @dr_mary_miller, @suvankarpal

  • Contributors Data collection was completed by KD, RQ, HS and CAC. RH reviewed the data and drafted the manuscript. The manuscript was reviewed and edited by SP, VB, MM, TB, JC and MC in addition to the other authors listed above. All authors are part of a working group currently looking at symptom management in prion disease, and working towards developing an evidence base and clinical guideline.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.